EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum

Husain Poonawala iD, Kathleen Davis iD, Myles E Kenny iD, Ares Alivisatos, Nhi Van, Tracy Washington iD, Vinicius Calado Nogueira de Moura iD, Charles L Daley, Bree B Aldridge iD

Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)

DOI: 10.1128/aac.01876-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Husain Poonawala und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Mycobacterium abscessus, Mycobacterium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NCATS NIH HHS, Infectious Diseases Society of America.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus is a drug-resistant pathogen associated with poor clinical outcomes despite prolonged treatment with multidrug antibiotic regimens. Apart from clarithromycin, antimicrobial susceptibility testing (AST) results for Mycobacterium abscessus cannot guide antibiotic selection. AST involves measuring the minimum inhibitory concentration (MIC), which is allowed to span a fourfold range in concentration. This accepted variability of the MIC limits the clinical utility of AST. Antimicrobial dose-response curves, obtained by measuring the growth inhibition of a given organism to increasing concentrations of an antibiotic, can yield metrics of antibiotic activity that are less variable than the MIC. We used Clinical and Laboratory Standards Institute growth conditions for rapidly growing nontuberculous mycobacteria AST to generate 990 dose-response curves across three time points (72 h, 96 h, and 120 h) for six guideline-recommended (clarithromycin, amikacin, cefoxitin, linezolid, tigecycline, and clofazimine) and five new (omadacycline, tedizolid, SPR719, SQ109, and bedaquiline) antibiotics against Mycobacterium abscessus subspecies abscessus ATCC 19977 and Mycobacterium peregrinum ATCC 700686. We established the fit of the dose-response curve ( R 2 ) as a quality control metric. Using the geometric standard deviation and median coefficient of variation, we demonstrated that the IC 50 and IC 75 (antibiotic concentrations corresponding to 50% and 75% growth inhibition, respectively) are less variable than the MIC. We identified time-dependent changes in dose-response curve metrics that allow the detection of inducible clarithromycin resistance with only 5 days of incubation. This study demonstrates the potential of dose-response curves in measuring antibiotic activity against Mycobacterium abscessus .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsMycobacterium abscessusMycobacteriumMicrobial Sensitivity TestsDose-Response Relationship, DrugClarithromycinAmikacinCefoxitinLinezolidTigecycline

Stichwörter der Autor:innen

Mycobacterium abscessusMycobacteroides abscessusantimicrobial activityantimicrobial susceptbility testingclarithromycindose-response curvesinducible resistancemultidrug resistance

Substanzen

Anti-Bacterial AgentsClarithromycinAmikacinCefoxitinLinezolidTigecycline

Autor:innen und Institutionen

  • Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
  • Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
  • Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, Massachusetts, USA.
  • Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
  • Divison of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, Colorado, USA.
  • Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.

ORCID-Profile: Husain Poonawala, Kathleen Davis, Myles E Kenny, Tracy Washington, Vinicius Calado Nogueira de Moura, Bree B Aldridge

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NCATS NIH HHS
  • Infectious Diseases Society of America
  • NIAID NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Poonawala, H., Davis, K., Kenny, M. E., Alivisatos, A., Van, N., Washington, T., Calado Nogueira de Moura, V., Daley, C. L., & Aldridge, B. B. (2026). Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.01876-25

Vancouver

Poonawala H, Davis K, Kenny ME, Alivisatos A, Van N, Washington T, et al. Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.01876-25

BibTeX
@article{Poonawala2026,
  author = {Poonawala, Husain and Davis, Kathleen and Kenny, Myles E and Alivisatos, Ares and Van, Nhi and Washington, Tracy and Calado Nogueira de Moura, Vinicius and Daley, Charles L and Aldridge, Bree B},
  title = {Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {5},
  doi = {10.1128/aac.01876-25}
}
Kostenlos starten →